Promegestone

Promegestone
Clinical data

ATC code	G03DB07 (WHO)
Identifiers
IUPAC name (8S,13S,14S,17S)-13,17-Dimethyl-17-propionyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
Synonyms	R-5020; RU-5020
CAS Number	34184-77-5
PubChem CID	36709
ChemSpider	33716
KEGG	D08431
ECHA InfoCard	100.207.681
Chemical and physical data
Formula	C₂₂H₃₀O₂
Molar mass	326.472 g/mol
3D model (Jmol)	Interactive image
SMILES CCC(=O)[C@]1(CC[C@@H]2[C@@]1(CCC3=C4CCC(=O)C=C4CC[C@@H]23)C)C
InChI InChI=1S/C22H30O2/c1-4-20(24)22(3)12-10-19-18-7-5-14-13-15(23)6-8-16(14)17(18)9-11-21(19,22)2/h13,18-19H,4-12H2,1-3H3/t18-,19+,21+,22-/m1/s1 Key:QFFCYTLOTYIJMR-XMGTWHOFSA-N

Promegestone (INN) (brand name Surgestone), also known as 17α,21-dimethyl-Δ⁹-19-norprogesterone or 17α,21-dimethyl-19-norpregna-4,9-diene-3,20-dione, is a steroidal progestin of the 19-norprogesterone group which was introduced in 1983 and is marketed in France, Portugal, and Argentina. Indications include gynaecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea, and premenstrual syndrome. Promegestone has weak glucocorticoid activity, but does not bind to the androgen receptor or possess antimineralocorticoid activity. In addition, promegestone has been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor, similarly to progesterone. The drug is mainly bound to albumin; it does not bind to sex hormone-binding globulin, and binds only weakly to transcortin.